Link Between Vitamin C and Twins Can Increase Seed Production in Crops

Discovery can assist farming of low-fertility crops, say UC Riverside biochemists

By Iqbal Pittalwala on June 18, 2012

RIVERSIDE, Calif. Biochemists at the University of California, Riverside report a new role for vitamin C in plants: promoting the production of twins and even triplets in plant seeds.

Daniel R. Gallie, a professor of biochemistry, and Zhong Chen, an associate research biochemist in the Department of Biochemistry, found that increasing the level of dehydroascorbate reductase (DHAR), a naturally occurring enzyme that recycles vitamin C in plants and animals, increases the level of the vitamin and results in the production of twin and triplet seedlings in a single seed.

The value of the discovery lies in the potential to produce genetically identical seedlings and increase production of high-value crops.

A boost of vitamin C results in the production of twin seedlings of tobacco. Photo credit: Gallie Lab, UC Riverside.

The ability to increase fertility can be extremely useful when the inherent rate of fertility is low or the value of the crop is great, such as corn in which the production of multiple embryos would significantly boost its protein content, Gallie said. The extra seedlings per seed may also enhance per-seed survival chances for some species.

Study results appear in the online international journal PLoS ONE.

Just as in humans, twins in plants can be either genetically identical or fraternal. Gallie and Chen discovered that the twins and triplets produced in tobacco plants when vitamin C was increased were true twins or triplets as they were genetically identical.

In the lab, the researchers went on to show that injecting plant ovaries with vitamin C was sufficient to produce twins or triplets and that the vitamin causes the zygote, the fertilized egg, to divide into two or even three fertilized egg cells before these cells proceed through subsequent stages of development to produce twins or triplets.

Go here to read the rest:
Link Between Vitamin C and Twins Can Increase Seed Production in Crops

Tracking breast cancer cells on the move

Public release date: 14-Jun-2012 [ | E-mail | Share ]

Contact: Angela Hopp 240-283-6614 American Society for Biochemistry and Molecular Biology

Breast cancer cells frequently move from their primary site and invade bone, decreasing a patient's chance of survival. This process of metastasis is complex, and factors both within the breast cancer cells and within the new bone environment play a role. In next week's Journal of Biological Chemistry "Paper of the Week," Roger Gomis and colleagues at the Institute for Research in Biomedicine in Spain investigated how breast cancer cells migrate to bone.

In particular, they examined the role of NOG, a gene important to proper bone development. Previously, NOG was associated with bone metastasis in prostate cancer, but its specific role in breast cancer to bone metastasis remained unknown.

Gomis and colleagues showed that once breast cancer cells are on the move NOG enables them to specifically invade the bone and establish a tumor. It does this in two ways. First, NOG escalates bone degeneration by increasing the number of mature osteoclasts (bone cells that break down bone), essentially creating a spot in the bone for the metastatic breast cancer cells to take up residence. Second, NOG keeps the metastatic breast cancer cells in a stem-cell-like state, which enables them to propagate and form a new tumor in the bone environment.

Gomis explains that the reason NOG expression leads to an increased potential for breast cancer to bone metastasis is because it not only affects features inherent to aggressive cancer cells (such as the ability to establish a new tumor) but also influences properties of the bone environment (such as osteoclast degeneration of bone).

###

From the article: "Identification of NOG as a specific breast cancer bone metastasis-supporting gene" by Maria Tarragona, Milica Pavlovic, Anna Arnal-Estap, Jelena Urosevic, Mnica Morales, Marc Guiu, Evarist Planet, Eva Gonzlez-Surez, Roger R. Gomis

Link to "Paper in Press": http://www.jbc.org/content/early/2012/04/30/jbc.M112.355834.full.pdf+html

Corresponding author: Roger R. Gomis, Oncology Programme, Institute for Research in Biomedicine in Barcelona, Spain; e-mail: roger.gomis@irbbarcelona.org

Read the original:
Tracking breast cancer cells on the move

MU biochemistry assistant professor Peter Cornish named Pew Scholar

Friday, June 15, 2012 | 7:45 p.m. CDT

COLUMBIA Peter Cornish has always been interested in discovery and figuring out how things function.

These interests have led him to national recognition.

Cornish, a biochemistry assistant professor at MU, is one of the22individuals in the nation to be named a 2012 Pew Scholar in the biomedical sciences.He is the first MU faculty member to receive the honor while working at the university.

It is a big deal for me and a big deal for the university, Cornish said. It not only provides money for research but also notoriety.

Pew Scholars are considered to be among the most innovative young researchers. According to the Pew Charitable Trusts website, the community includes Nobel Prize winners, MacArthur Fellows and Albert Lasker BasicMedical Research Award recipients.

Since 1985, the program has invited top research institutions to nominate one candidate each year. It received 134 eligible nominations from a pool of 179 institutions this year.

Winners receive $240,000over four years to help them pursue their research without major restrictions.The program looks to back scientists early in their careers so they can take calculated risks to help advance the human health field.

Even though Cornish only started at MU in the spring of 2010, his talent, past work and future potential made him a great fit to be MUs Pew Scholar nominee, said Gerald Hazelbauer, chairman of the Biochemistry Department.

Cornish is working with technologycalled Frster resonance energy transfer (FRET), which is relatively new and developing quite rapidly, Hazelbauer said. Single-molecule FRET gives scientists the ability to look at molecules on an individual basis.

View original post here:
MU biochemistry assistant professor Peter Cornish named Pew Scholar

Brainiac: The history and science of doping

The return of the Olympics means that we'll get to enjoy some of those weird and delightful summer sports -- stuff like archery, handball, and synchronized swimming. Unfortunately, it also means the return of a thorny and frustrating subject: doping. In Run, Swim, Throw, Cheat, Chris Cooper, a professor of biochemistry at the University of Essex, provides an extraordinarily thorough account of the history and science of drugs in sports. We tend to think about doping in a relatively unsophisticated way, Cooper argues: It's bad, and we want to stop it. In fact, however, the science of doping is extraordinarily complex, and its history is nuanced and surprising. We need to understand doping better.

The first thing to grasp about doping, Cooper writes, is that, for most of history, no one's cared about it -- the idea of "doping" simply didn't exist. The ancient Greeks were entirely open about their use of nutritional and pharmaceutical aides: "Charmis of Sparta swore that dried figs led him to Olympic gold in 668 B.C.," Cooper writes, while the great Greek physician Galen "noted the positive benefits of eating herbs, mushrooms, and testicles." In 1904, runner Thomas Hicks won the St. Louis Olympic Marathon "on a combination of strychnine injections laced with brandy," and no one seemed to mind; in the inter-war years, scientists on both sides of the Atlantic openly and enthusiastically endorsed performance-enhancing drugs, including cocaine. In the 1930s, British soccer teams proudly boasted about the supplements they used: the Wolverhampton Wanderers, for example, "informed the media of their latest pharmaceutical tricks, publicizing their use of extracts of monkey glands in the newspaper the News of the World." Doping was banned at the Olympics in 1938, but still didn't have a real stigma -- professional athletes continued to use drugs.

For most of history, Cooper writes, "The debate, as far as we can judge, was about methods not morals. The view seemed to be that any way to obtain an edge was fine." Really, Cooper argues, it should come as no surprise that no one cared about doping: Ordinary people were enthusiastic about drugs in everyday life, too. In the 1940s and 50s, it was totally normal for a person to pop an amphetamine pill to boost his mood. It was only when society as a whole turned against drugs after the 1960s that doping in sports became a truly moral issue.

So we are still working out own attitudes toward doping, which are relatively recent -- and those attitudes must contend with the science of doping, which, Cooper shows, is equally double-edged. In the first place, it's hard to know what really works -- and, therefore, which offenses an athlete ought to be punished for. Clinical trials of performance-enhancing drugs, he points out, are of limited relevance to elite athletes, since they have bodies which differ in substantial ways from those of even very fit ordinary people. And, at the highest levels, elite athletes often possess built-in advantages which are 'unfair,' and which can be arranged on a spectrum along with pharmaceutical or nutritional advantages. Some athletes, for example, are "doped" by their genes -- like the Finnish skier Eero Mantyranta, who won seven Olympic medals, in part because he possessed a mutant gene which caused his body to over-produce EPO, a hormone which drives the production of red blood cells. EPO, as it happens, is also a performance-enhancing drug. Similarly, a small percentage of female athletes, Cooper points out, are born with hormonal profiles which give them unusual strength and speed. Above and beyond these issues, there's the fact of "technological doping" -- the benefits which an economically advanced home country can provide for an athlete-in-training.

Doping, in short, is complicated, and hard to talk about in a monolithic way. The only way to make sense of it is to think very carefully, on a case-by-case basis, about which sorts of interventions constitute effective, meaningful cheating. (Some doping interventions might in fact boil down to the placebo effect.) Unfortunately, our approach to doping is as inconsistent as our policy on recreational drugs. Caffeine, for example, has a demonstrable and substantial affect on athletic performance, and yet no one's outlawed it -- almost certainly because it's legal in civilian life. This suggests that many of our attitudes about doping may have little to do with sports. Instead, they proceed out of our moral concerns about drug use in general.

Cooper devotes most of the book to a fine-grained discussion of the science of doping, and shows that it's full of surprising wrinkles and exceptions. As a whole, his account suggests that we are not spending enough money and time to really understand the problem. Ultimately, he makes the case for a more empirical and pro-active approach to thinking about drugs in sports, driven by research. More research would help us anticipate new developments and concentrate on those doping practices which truly create unfairness. "We can no more 'win' a war on drugs in sport than we can 'win' a war on drugs in society," he concludes -- the best we can do is be informed, and to focus on increasing fairness, one case at a time.

See original here:
Brainiac: The history and science of doping

UNC's Saskia Neher selected as 2012 Pew Scholar

Newswise CHAPEL HILL, N.C. - Saskia B. Neher, PhD, assistant professor in the department of biochemistry and biophysics at the University of North Carolina School of Medicine, was one of twenty-two of Americas most promising scientists to be named Pew Scholars in the Biomedical Sciences by the Pew Charitable Trusts.

Neher is the eleventh such recipient for UNC since the program began in 1985 and she is one of 8 women among 22 awardees, overall, nationwide.

The 2012 Pew Scholars will join a select community that includes MacArthur Fellows, recipients of the Albert Lasker Medical Research Award and three Nobel Prize winners. The program encourages early-career scientists to advance research that leads to important medical breakthroughs and treatments.

Nehers research explores the molecular systems that help to activateand disablethe breakdown of fat. When we consume food rich in fat, molecules called lipases break down the fat so that it can be used as a source of fuel or be stored. In humans, defects in a lipase called LPL increase an individuals risk of cardiovascular disease. The activity of this molecule is regulated by a pair of proteins: one that activates LPL and another that switches it off when an animal fasts. Neher uncovered evidence that suggests how the activating protein functions.

Nehers work now will be to determine how the regulators of LPL interact, using sophisticated approaches in biochemistry, molecular biology and crystallography. Her research should provide insights into the regulation of an important process that could produce new targets for the treatment or prevention of cardiovascular disease.

Pew is pleased to provide this countrys most ambitious and dedicated scientists with timely funding that enables them to explore novel areas of investigation early in their careers, at what may be the most inventive and creative period in their research, said Rebecca W. Rimel, president and CEO of The Pew Charitable Trusts.

The program has invested more than $125 million to fund over 500 scholars. Recipients receive $240,000 over four years to pursue their research without restriction. Applicants are nominated by an invited institution and demonstrate both excellence and innovation in their research. This year, 179 institutions were requested to nominate a candidate and 134 eligible nominations were received.

View original post here:
UNC's Saskia Neher selected as 2012 Pew Scholar

Did Lance Try to Fly Under the Radar?

Seven-time Tour de France champ and cancer activist Lance Armstrong is back in the news, but not for great physical feats.

This time, hes defending himself against doping charges that could strip him of the seven Tour de France titles that he won from 1999 to 2005.

While many of the allegations have been raised before, and were the subject of a federal investigation that concluded several months ago with no criminal charges, there is some surprising new evidence that Armstrong continued to dope during his "comeback" to professional cycling from 2009 to 2011.

PHOTOS: Lance Armstrong: Cycling Legend

It seems odd he would continue, said Thomas Brenna, professor of nutritional science at Cornell University and researcher into the use of steroids in sports.

Brenna says that even though Armstrong did not fail any doping tests, his biochemistry may have been suspicious enough to raise alarm bells by U.S. Anti-Doping Agency officials.

They are charging that he was flying under the radar, Brenna said. That indicates that they believe that based on the totality of the evidence that he has been systematically been doping and avoiding detection in same sense that the BALCO folks (the San Francisco Bay Area lab linked to doping violations by Giants slugger Barry Bonds and Olympic sprinter Marion Jones) were keeping track of when one could dope and take a test and pass it.

According to the allegations by USADA, Armstrong figured out a way to get a performance benefit from blood-boosting drugs without tripping the wire.

Yes, there are ways to fool the test if you know what you are doing, said Brenna. Im not going to say how.

The charges against Armstrong and five former team officials and team doctors were contained in a June 12 letter from USADA. The letters existence was first revealed by The Washington Post and has been published by the Wall Street Journal.

Visit link:
Did Lance Try to Fly Under the Radar?

Novel biochemistry in Bovine immunodeficiency virus [erv]

Many roads lead to Rome there is no one right way to solve an evolutionary hurdle. Viruses encounter the same evolutionary problems, but have evolved lots and lots and lots of different solutions to the exact same problems. Random chance of mutations + the bumbling blindness of natural selection (good enough is selected, not BEST!) means all that bumbling mess leads to different solutions. Some might work better than others, but they all work, and thats good enough.

Its easy to comprehend an RNA virus doing something differently than a very distantly related DNA virus. But differences exist between closely related viruses as well. We all know no-new-genes-no-new-functions Michael Behe and his Creationist BFFs hate the evolutionary capacity of new-genes-new-functions HIV-1. They have to hate its cousin Bovine immunodeficiency virus too:

The bovine immunodeficiency virus Rev protein: identification of novel nuclear import pathway and nuclear export signal among retroviral Rev/Rev-like proteins

There are lots of different ways to get a protein. Retroviruses operate like a sheet cake it makes one bit mRNA that gets cuts up into lots of little mRNAs as it leaves the nucleus, which go one to be translated into all the proteins the retrovirus needs.

But then how to you get a retroviral genome into the babby viruses? The retroviral genome is a big uncut piece of mRNA. If it always gets cut up when it leaves the nucleus, how can you ever get that big uncut RNA genome into new viruses?

Lentiviruses have an answer to this dilemma Regulator of Virion Expression, Rev.

Rev escorts the mRNA out of the nucleus, so it can be chopped up in different ways to get different retroviral proteins, or, prevent the RNA from being cut entirely so full genomes can be packaged into babby viruses.

And of course, its not just about Rev getting out of the nucleus with its RNA companion. It must also be able to get itself into the nucleus. Proteins like Rev are made in the cytoplasm on ribosomes it needs to perform a few tricks to get itself into the nucleus to pick up its RNA buddy.

So Rev does two things gets into the nucleus, gets out of the nucleus with RNA. Gets into the nucleus, gets out of the nucleus with RNA. Over and over.

You would think that Rev from HIV and Rev from BIV would look and behave in the same manner. Theyre the same protein from the same family of retrovirus (lentivirus) that accomplish the same function.

Follow this link:
Novel biochemistry in Bovine immunodeficiency virus [erv]

Research and Markets: Comprehensive Chiroptical Spectroscopy, 2 Volume Set

DUBLIN--(BUSINESS WIRE)--

Dublin - Research and Markets (http://www.researchandmarkets.com/research/psxwcg/comprehensive_chir) has announced the addition of John Wiley and Sons Ltd's new book "Comprehensive Chiroptical Spectroscopy, 2 Volume Set" to their offering.

This two-volume set provides an introduction to the important methods of chiroptical spectroscopy in general, and circular dichroism (CD) in particular, which are increasingly important in all areas of chemistry, biochemistry, and structural biology.

The set can be used as a text for undergraduate and graduate students and as a reference for researchers in academia and industry, with or without the companion volume in this set.

Experimental methods and instrumentation are described with topics ranging from the most widely used methods (electronic and vibrational CD) to frontier areas such as nonlinear spectroscopy and photoelectron CD, as well as the theory of chiroptical methods and techniques for simulating chiroptical properties.

Each chapter is written by one or more leading authorities with extensive experience in the field.

Key Topics Covered:

PART I INTRODUCTION

1 ON THE INTERACTION OF LIGHT WITH MOLECULES: PATHWAYS TO THE THEORETICAL INTERPRETATION OF CHIROPTICAL PHENOMENA

2 MEASUREMENT OF THE CIRCULAR DICHROISM OF ELECTRONIC TRANSITIONS

More here:
Research and Markets: Comprehensive Chiroptical Spectroscopy, 2 Volume Set

Stover honored with MERIT award for folate research

June 5, 2012

Stover honored with MERIT award for folate research

For his long-running research on the molecular genetics and biochemistry of the vitamins folate and vitamin B-12, and their link to colon cancer, cardiovascular disease and human birth defects, Patrick Stover, professor of nutritional biochemistry and director of Cornell's Division of Nutritional Sciences, has received a prestigious MERIT (Method to Extend Research in Time) award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

In the award letter from NIDDK, part of the National Institutes of Health (NIH), Stover is cited for his "consistent and excellence contributions to scientific knowledge" on the subject. Among his breakthrough findings: the identification of a gene that increases the risk for colon cancer in laboratory mice when their diets lack folate; the genetic underpinnings of mitochondrial depletion syndrome in humans; and, in mice, the discovery of a gene that causes neural tube defects.

MERIT awards provide recipients with stable, long-term research funding, freeing them from the administrative burden of submitting their work for regular renewals and reviews. With the award, Stover will receive 10 years of uninterrupted support for his research on folate (vitamin B-9) and vitamin B-12.

"I am grateful to NIH-NIDDK for their continuous support of my research program since I arrived at Cornell as an assistant professor in 1994, and for giving me the security and opportunity to undertake high-risk/high-reward fundamental research through this MERIT award," Stover said. "I value my continuing relationship with this important NIH institute, which has played such a pivotal role in advancing our understanding of fundamental metabolism and nutrition and the molecular basis of human chronic disease."

Stover had previously received the Presidential Early Career Award for Scientists and Engineers and the E.L.R. Stokstad Award in Nutritional Biochemistry from the American Society for Nutrition.

Ted Boscia is assistant director of communications for the College of Human Ecology.

##

View post:
Stover honored with MERIT award for folate research

Enamine, MRC LMB and IOCB Announce Collaboration to Identify Novel Rhomboid Protease Inhibitors for Treatment of …

KIEV, Ukraine--(BUSINESS WIRE)--

Enamine Ltd, a leading provider of screening compounds, chemical building blocks and discovery services, today announced that it has signed a collaboration agreement with the Medical Research Council Laboratory of Molecular Biology (MRC LMB), Cambridge, UK, and the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (IOCB), Prague, Czech Republic.The new alliance is aimed at discovering novel Rhomboid Protease inhibitors as potential drugs to treat infectious, parasitic, oncological, immune and cardiovascular diseases.

Under the terms of the agreement, Enamine will provide the MRC LMB and IOCB with access to its integrated drug discovery capabilities, including Molecular Modeling, Compound Library, Screening Assays, Hit Finding and Characterization, Hit to Lead Chemistry and ADMET. The three parties will jointly own the Intellectual Property resulting from this programme and will seek to partner the small molecule inhibitors generated with pharmaceutical companies for onward clinical development. The collaboration agreement was negotiated by MRC Technology on behalf of MRC LMB.

Dr. Sergey Zozulya, Vice President, Biology at Enamine, said: "We are delighted to launch this collaboration with high calibre partners, demonstrating the interest of prominent academics in realising the translational potential of their scientific discoveries through an alliance with Enamine. This alliance reflects our strategy to apply our integrated discovery platform, cost effective solutions and state-of-the-art technologies to create valuable IP for our partners and clients. With our recently introduced High Throughput Screening and bioanalytical service components, we have added capability to boost productivity."

Dr. Matthew Freeman, Head of Cell Biology Division at MRC LMB, commented: "We anticipate a very successful relationship with Enamine. This project provides evidence of the ability of our respective research centers to recognize valuable drug discovery models.

Dr. Kvido Strisovsky, Group Leader at IOCB, said: "We are delighted to be part of this collaboration and we hope that the project will realise its full potential for the benefit of patients.

ENDS

About Enamine http://www.enamine.net

Established in Kiev in 1991, Enamine is a medicinal chemistry driven company, provider of innovative screening libraries, comprehensive chemistry support in hit development, and integrated drug discovery services.

About the MRC Laboratory of Molecular Biology http://www2.mrc-lmb.cam.ac.uk/about-lmb

Here is the original post:
Enamine, MRC LMB and IOCB Announce Collaboration to Identify Novel Rhomboid Protease Inhibitors for Treatment of ...

Shippen honored as Faculty Fellow by Texas AgriLife Research

Writer: Kathleen Phillips, 979-845-2872, ka-phillips@tamu.edu Contact: Dr. Dorothy Shippen, 979-862-2342, dshippen@tamu.edu

COLLEGE STATION Dr. Dorothy Shippen, professor of biochemistry and biophysics, has received the Texas AgriLife Research Senior Faculty Fellow Award.

The faculty fellows program, created in 1998, recognizes people who have contributed to the scholarly creation and dissemination of new knowledge through exceptional research leadership and grantsmanship.

Professors and associate professors in the College of Agriculture and Life Sciences at Texas A&M University who hold a joint appointment with AgriLife Research are eligible for the senior faculty fellow honor and $5,000 award.

Shippen was honored with Dr. Del Gatlin, fisheries researcher, and Dr. Bruce McCarl, agricultural economist, both of whom also received Senior Faculty Fellow awards, and with Dr. Binayak Mohanty, who was named Faculty Fellow.

I am extremely proud of these scientists whose studies have brought great advances in their fields and to the benefit of the public and our agency, said Dr. Craig Nessler, AgriLife Research director. Their scientific endeavors are yielding results that positively impact people in our state, nation and world.

Shippens studies on telomerase an enzyme which has special significance to aging and cancer research, led to 16 scientific papers being published in the last five years, according to her nomination. Among the journals that have published her research are Nature, Science and the Proceedings of the National Academy of Science.

Dr. Shippen rapidly carved a unique scientific niche for herself, as she is now unquestionably the worlds expert in this subfield of telomerase research, said Dr. Greg Reinhart, Texas A&M department of biochemistry and biophysics chair. The excitement derives not just from the important implication of her work for plant science, but also because this model organism, despite being a plant, is in many ways a better model of mammalian telomerase behavior than the more commonly studied organisms.

The citation noted that Shippen is frequently invited to speak at major scientific conferences and is known for her rigorous but popular teaching ability in college courses such as molecular biology and for her involvement in numerous scientific associations.

Shippen earned her bachelors in biology in 1982 from Auburn University and her doctorate in biology in 1987 from the University of Alabama.

Continued here:
Shippen honored as Faculty Fellow by Texas AgriLife Research

BVU student selected for DMU health professions program

Chelsea Clayton, a triple biology, chemistry and biochemistry major at BVU, will be one of 10 students attending an advanced health professions summer program at Des Moines University. / submitted photo

"I am one of two students from the state of Iowa that will be participating in this program," Chelsea says. "The other eight students come from Washington, Nebraska, Illinois, Pennsylvania, Florida, California and Michigan."

This three-week program exposes students to the four advanced clinical degrees offered at DMU. All costs associated with accommodations, transportation and food are covered by DMU.

"Through this program, I will have the opportunity to learn from lectures and presentations in DMU's four clinical areas - osteopathic medicine, podiatric medicine and surgery, physical therapy and physician assistant studies," says Chelsea.

"I will also have the opportunity for hands-on experiences as well as job shadowing doctors and other care providers in the DMU clinic. On top of all that, I will learn how to plan for medical/health professions school and participate in mock interviews to enhance my preparation for medical school. I believe this program will impact my career goals by helping me decide what area of medicine I actually want to go into. It will give me the additional tools I need to get into medical school and accomplish my dream of becoming a doctor."

Chelsea learned of the opportunity from BVU faculty and says her relationships with her professors have had a major impact on her learning and career decisions.

"Aside from being exceptionally well at what they do in the classroom, BVU's professors have also encouraged me outside the classroom and I know that I am more than just 'another student' to them."

"I know that my professors truly care about me, and because of that it has motivated me to accomplish even more than what I would have anywhere else," says Chelsea.

"BVU's facilities and programs have also helped to prepare me for this program. I believe that BVU has one of the nicest science centers I have seen, and the access to the research equipment that BVU has available to students is amazing."

Read the original here:
BVU student selected for DMU health professions program

Raiders' professor of defense

It's a good thing that Jason Tarver mastered (as in degree) biochemistry and molecular biology. Because he is taking on much uglier, more complicated material now.

How are the Raiders going to stop the run?

And when he's done with that decade-old problem, Oakland's bright-eyed new defensive coordinator can tackle this brainteaser:

How are the Raiders going to stop the pass?

Oakland, which won eight games last season on the strength of its offense, became one of four teams to allow at least 30 TD passes and 5.0 yards per carry in a season. (Not to mention the entire squad's NFL-record 163 penalties for 1,358 yards.) The Raiders had a lot of high-priced players, but few, if any, playmakers on defense.

And then, in the offseason, Oakland cut leading pass-rusher Kamerion Wimbley for salary-cap reasons and also let go of its two starting cornerbacks, Stanford Routt and Chris Johnson.

The Raiders replaced them with several veterans signed to one-year contracts and rookies drafted after the second round, as they didn't have any early picks.

All of which explains why Tarver can't go into a lot of detail when asked what the Raiders' defense is going to look like. He doesn't know yet.

The team was back on the field for organized workouts Monday, Tuesday and Wednesday, and Tarver and new head coach Dennis Allen are still in discovery mode.

"Put all these guys out here and see who can play and who can learn and who can communicate and who can fit with your group," Tarver said.

Follow this link:
Raiders' professor of defense

Biologists construct self-assembling tiles of DNA

Harvard biologists have brought new meaning to the term "fine print" by devising microscopic tiles made of DNA that self-assemble into letters, Chinese characters, emoticons and other shapes.

More than mere doodling, their advance, detailed this week in the journal Nature, could make it easier and cheaper to build tiny DNA devices capable of delivering drugs or aiding the study of biochemistry, scientists said.

"This technique will accelerate the research field of DNA nanotechnology," said Ebbe Sloth Andersen, a researcher at Aarhus University in Denmark who collaborated on an editorial that accompanied the report.

In its usual role as a warehouse for storing genetic information, DNA helps build humans and hummingbirds, maple trees and meerkats all sorts of complex organisms. But as a building material for machines smaller than the smallest bacterium, it has been tough to control.

Since the early 1980s, engineers have experimented with a variety of approaches to create structures out of DNA, including the use of tiles small bricks woven together out of several strands of DNA that could stick to one another and self-assemble into shapes.

But when researchers tried to construct precisely defined shapes, they ran into trouble, said Peng Yin, a systems biologist at Harvard's Wyss Institute in Boston and senior author of the Nature study. The tiles tended to stick together incorrectly, resulting in incomplete structures.

"People thought this couldn't work," Yin said.

But he and his collaborators pressed on, ultimately designing bricks out of single rather than multiple strands of DNA.

The strands each had four sequences of 10 or 11 bases, which could bind to complementary sequences of 10 or 11 bases on other tiles. If all four sequences on the edges of a tile bind with their matching counterparts on neighboring tiles, the tile assumes a rectangular shape.

The scientists programmed the tiles to stack up in a staggered formation, like a miniature brick wall. Then they created shapes by leaving out tiles at certain locations of their 64-by-103-nanometer "molecular canvas."

Visit link:
Biologists construct self-assembling tiles of DNA

Around Iowa State University: June 3

ISU proposes department name

Pending approval by the Iowa Board of Regents, Iowa State Universitys Department of Biochemistry, Biophysics and Molecular Biology will be named in honor of the Roy J. Carver Charitable Trust, in recognition of gifts and commitments to the department totaling more than $12.3 million.

This support includes a $7.5 million commitment announced Thursday to support strategic research initiatives in biomolecular structure.

Also known as structural biology, this scientific field seeks to better understand basic biomolecular function, which can hold the key to unlocking important new discoveries in wide-ranging areas important to human, plant and animal life.

With the regents approval, the new name will be the Roy J. Carver Department of Biochemistry, Biophysics and Molecular Biology.

ISU grads give scholarships

Benches, plaques, art, fountains these are typical class gifts. Tangible things you can sit on, gaze upon, drink from.

Cognizant of the growing financial pressures on college students, ISUs class of 2012 opted to leave something different to the alma mater. The class set up an endowment that will fund scholarships for upperclassmen.

Thus far, more than 600 recent graduates have pledged $45,400 to the scholarship fund.

Thats an average of $74 per graduate, said Sarah Johnson, a program manager in the ISU Foundation. And we expect the endowment to grow in the next couple of weeks as student fundraisers finish making contacts with the graduating seniors.

View original post here:
Around Iowa State University: June 3

Madison masterpieces: John Steuart Curry murals, UW Biochemistry Building

On a stroll through the UW campus, there's plenty of art to see, from the newly expanded Chazen Museum of Art to galleries within Memorial Union and Union South.

But not all of the university's artistic treasures are in places you might expect. Take the stairwell of the recently renovated Biochemistry Building. There you'll find murals by the renowned American painter John Steuart Curry that are not only fascinating in their own right, but also a testament to a forward-thinking collaboration between the sciences and arts.

Curry, part of a trio of famed regionalists along with Grant Wood and Thomas Hart Benton, was invited to the UW in 1936 as artist-in-residence. While such arrangements are now common at schools across the country, Curry's position was the first of its kind in the nation and it was through the College of Agriculture, not the art department.

The 1940s mural The Social Benefits of Biochemical Research dramatically depicts the gains brought by vitamin discoveries and applications by leading UW researchers such as Harry Steenbock.

Sickly children and animals contrast with vibrant, healthy kids and livestock striding forward. Spread over three walls in the octagonal stairwell, the main panel exudes a sincere conviction in human progress and the ability of science to make life better. Additional panels in the stairwell show lush cornstalks waving in the wind and an idyllic farm where roosters, sows, calves and other critters thrive.

A nearby conference room contains more Curry murals, and works by Curry are also in the permanent collections of the Chazen and the Madison Museum of Contemporary Art.

Here is the original post:
Madison masterpieces: John Steuart Curry murals, UW Biochemistry Building

Memoir tracks the life, decline and death of a family farm

Public release date: 30-May-2012 [ | E-mail | Share ]

Contact: Diana Yates diya@illinois.edu 217-333-5802 University of Illinois at Urbana-Champaign

CHAMPAIGN, Ill. There is no sentimentality in Robert Switzer's modestly titled new book, "A Family Farm: Life on an Illinois Dairy Farm." Switzer, an emeritus professor of biochemistry at the University of Illinois, begins with a quote (from Victor Davis Hanson's own book on farming) that "the American yeoman farmer is doomed," and describes the internal and external forces that led to the demise of his family's farm in northwest Illinois.

The story of the Allison-Switzer farm (named for Switzer's maternal grandparents, who bought the 121-acre property in 1916, and his father and mother, who took it over after her parents retired in 1946) is just one of millions of such stories, Switzer writes.

"In 1900, 42 percent of the U.S. population lived on farms; by 1990 that number had dwindled to less than 2 percent," he says in the book's prologue. This transition occurred largely as a result of economic and technological changes made possible by the aggressively optimistic borrowing, investing and expansion that some farmers were willing to embrace in the latter half of the 20th century. Many other farmers, who had stared down economic catastrophe in the 1920s and '30s, were unwilling to take on new big risks, and their farms generally gave way to the forces favoring consolidation and the mass-production of agricultural commodities. (Watch an audio slide show about the book.)

Switzer's book is not a treatise on the evolution of American farming, however.

"The characters in this story are not statistical stick figures illustrating the decline of a Midwestern family farm," he writes. "They are my family. The details of their lives provide an intimate portrait of a once common way of life, now almost entirely vanished from the American countryside."

This portrait includes details normally left out of family memoirs: his maternal grandmother's hostility to her daughter's intellectual and educational aspirations; his grandfather's recurrent narcolepsy, a lifelong handicap brought on by severe heatstroke suffered while working in the fields as a teenager; Switzer's mother's depression and unhappiness with farm life; and his father's inability to recruit his sons to the profession.

The book also offers an account of the changes that occurred over the 76 years the family owned the farm, from the early days of kerosene lamps, hand milking and horse-drawn plows, to the gradual though never fully realized modernization of equipment and farming techniques.

Switzer begins with the gritty details of his grandparents' daily life. Charlie and Mabel Allison milked their cows twice daily in a drafty barn. They lived in an oversized and poorly insulated farmhouse with no modern conveniences. They grew corn, hay, oats and barley to feed their livestock and themselves. Charlie carted fresh milk to a nearby cheese factory every morning. Mabel kept a vegetable garden and orchard, and canned produce for the winter. The couple raised chickens and sold their eggs.

View original post here:
Memoir tracks the life, decline and death of a family farm

On early Earth, iron may have performed magnesium's RNA folding job

Public release date: 31-May-2012 [ | E-mail | Share ]

Contact: Abby Robinson abby@innovate.gatech.edu 404-385-3364 Georgia Institute of Technology Research News

On the periodic table of the elements, iron and magnesium are far apart. But new evidence suggests that 3 billion years ago, iron did the chemical work now done by magnesium in helping RNA fold and function properly.

There is considerable evidence that the evolution of life passed through an early stage when RNA played a more central role before DNA and coded proteins appeared. During that time, more than 3 billion years ago, the environment lacked oxygen but had an abundance of soluble iron.

In a new study, researchers from the Georgia Institute of Technology used experiments and numerical calculations to show that iron, in the absence of oxygen, can substitute for magnesium in RNA binding, folding and catalysis. The researchers found that RNA's shape and folding structure remained the same and its functional activity increased when magnesium was replaced by iron in an oxygen-free environment.

"The primary motivation of this work was to understand RNA in plausible early earth conditions and we found that iron could support an array of RNA structures and catalytic functions more diverse than RNA with magnesium," said Loren Williams, a professor in the School of Chemistry and Biochemistry at Georgia Tech.

The results of the study were published online on May 31, 2012 in the journal PLoS ONE. The study was supported by the NASA Astrobiology Institute.

In addition to Williams, Georgia Tech School of Biology postdoctoral fellow Shreyas Athavale, research scientist Anton Petrov, and professors Roger Wartell and Stephen Harvey, and Georgia Tech School of Chemistry and Biochemistry postdoctoral fellow Chiaolong Hsiao and professor Nicholas Hud also contributed to this work.

Free oxygen gas was almost nonexistent more than 3 billion years ago in the early earth's atmosphere. When oxygen began entering the environment as a product of photosynthesis, it turned the earth's iron to rust, forming massive banded iron formations that are still mined today. The free oxygen produced by advanced organisms caused iron to be toxic, even though it was -- and still is -- a requirement for life.

This environmental transition triggered by the introduction of free oxygen into the atmosphere would have caused a slow, but dramatic, shift in biology that required transformations in biochemical mechanisms and metabolic pathways. The current study provides evidence that this transition may have caused a shift from iron to magnesium for RNA binding, folding and catalysis processes.

Read the original post:
On early Earth, iron may have performed magnesium's RNA folding job

Research and License Agreements between National Cheng Kung University and Novo Nordisk A/S

TAINAN, Taiwan--(BUSINESS WIRE)--

A southern Taiwan-based National Cheng Kung University (NCKU) research team led by Ming-Shi Chang, NCKU professor of the Department of Biochemistry and Molecular Biology, has discovered an anti-interleukin-20 (anti-IL-20) antibody, a potential new anti-osteoporosis and anti-rheumatoid arthritis drug, and agrees to license selected intellectual property and transfer certain technology to Novo Nordisk A/S, a Danish-based pharmaceutical company for a total payment of US$ 13.3 million in case of a successful completion of the project.

In addition, Professor Ming-Shi Chang and Novo Nordisk A/S have established a 2-year research collaboration to further strengthen and possible expand the usages of an IL-20 antibody.

NCKU President Hwung-Hweng Hwung hailed the groundbreaking discovery of anti-interleukin-20 antibody: The findings not only mark a milestone in global healthcare, but also raise the visibility of Taiwans academic research.

This medical discovery was published in the Journal of Experimental Medicine (JEM) and has drawn huge attention in the academic world and the biotechnology industry as well.

IL-20 has a key role in osteoclast differentiation, and blockading this cytokine could represent a novel therapeutic approach for osteoporosis, according to data from the NCKU medical team.

The chief editor of Nature Reviews wrote a research highlight in the September issue of Nature Reviews Rheumatology commenting on this finding, while Science-Business eXchange (SciBX) published a cover story reporting on the discovery in the same month.

The study not only signifies groundbreaking findings in the pathogenesis of osteoporosis, but could lead to the innovation of new drugs to treat osteoporosis and rheumatoid arthritis.

Professor Chang pointed out that the medical expense of anti-osteoporosis drugs for patients around the world is estimated to be as much as US$8 billion per year, and that the amount spent on them by 2015 will be about US$8.8 billion.

Changs team has discovered that IL-20 is an important factor in bone cell differentiation and that high serum IL-20 levels in osteoporosis patients cause bone destruction.

See the original post here:
Research and License Agreements between National Cheng Kung University and Novo Nordisk A/S

CEM President and CEO Delivers Commencement Address at the 2012 University of Texas at Austin Chemistry and …

MATTHEWS, N.C., May 25, 2012 /PRNewswire/ --CEM Corporation president and CEO Michael J. Collins delivered the commencement address for the University of Texas at Austin Chemistry and Biochemistry Department, which was held on May 18, 2012. Collins received his PhD in Physical Chemistry from the University and has been a member of the Advisory Board for the Chemistry Department at the school for a number of years.

(Logo: http://photos.prnewswire.com/prnh/20090622/CL35336LOGO-b )

"I am honored to have been asked to deliver the commencement address again this year," said Michael J. Collins. "UT's encouragement of science and innovation has resulted in a thriving chemistry and biochemistry program whose graduates rank at the top of their professions. I enjoyed speaking to this year's graduates and I look forward to the scientific discoveries and contributions they will make in the years to come."

Collins told the audience about his time at the University of Texas at Austin and how it helped shape his life as a chemist, entrepreneur, and business leader. He advised graduates to disregard the defeatists that have been predicting a worsening of the economy and a lack of opportunities.

"I predict we are on the verge of a major new era of growth for the US which will exceed anything we have seen in the past," said Collins, who believes the growth will be driven by continuing technological advancements in many fields including medicine, material science, and energy production and the ongoing globalization of business as new markets open up in developing countries.

Collins also sees a coming revitalization of American manufacturing through entrepreneurial innovation and breakthroughs in technology.

"Science-based technology companies will continue to change the world. Chemistry and biochemistry will drive many of these companies," said Collins. "Your goal is to go forward and truly become our greatest generation ever."

Collins encouraged the graduates to find something they are passionate about and to pursue it with all their energy and determination.

"Whatever you decide to do, be the absolute best at it and keep challenging yourself," Collins encouraged. "Always be prepared, but be bold and think big."

A prepared text of Dr. Collins' commencement address is available on CEM's website at http://www.cem.com.

Read this article:
CEM President and CEO Delivers Commencement Address at the 2012 University of Texas at Austin Chemistry and ...